<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540539</url>
  </required_header>
  <id_info>
    <org_study_id>R1154-HV-1116</org_study_id>
    <nct_id>NCT01540539</nct_id>
  </id_info>
  <brief_title>Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the safety and tolerability of intravenous (IV) and&#xD;
      subcutaneous (SC) administration of REGN1154 in normal healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number and severity of TEAEs</measure>
    <time_frame>Day 1 through Day 113</time_frame>
    <description>TEAEs (Treatment-emergent adverse events)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration</measure>
    <time_frame>Day 1 through Day 113</time_frame>
    <description>Serum concentrations of REGN1154 over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of antibodies</measure>
    <time_frame>Day 1 through Day 113</time_frame>
    <description>Presence or absence of antibodies against REGN1154 over time.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Dosing cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1154 or placebo</intervention_name>
    <description>Participants will receive active drug or placebo</description>
    <arm_group_label>Dosing cohort 1</arm_group_label>
    <arm_group_label>Dosing cohort 2</arm_group_label>
    <arm_group_label>Dosing cohort 3</arm_group_label>
    <arm_group_label>Dosing cohort 4</arm_group_label>
    <arm_group_label>Dosing cohort 5</arm_group_label>
    <arm_group_label>Dosing cohort 6</arm_group_label>
    <arm_group_label>Dosing cohort 7</arm_group_label>
    <arm_group_label>Dosing cohort 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy men and women between the ages of 18 and 65; women must be postmenopausal or&#xD;
             surgically sterile&#xD;
&#xD;
          2. Body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive&#xD;
&#xD;
          3. Willing, committed, and able to return for ALL clinic visits and complete all&#xD;
             study-related procedures&#xD;
&#xD;
          4. Able to read or to understand the consent process, and willing to sign the informed&#xD;
             consent form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria include, but are not limited to the following:&#xD;
&#xD;
          1. Any illness or condition that would adversely affect the subject's participation in&#xD;
             this study&#xD;
&#xD;
          2. Any clinically significant abnormalities observed during the screening visit&#xD;
&#xD;
          3. Use of certain medications taken before the screening visit&#xD;
&#xD;
          4. Onset of a new exercise routine or major change to a previous exercise routine within&#xD;
             4 weeks prior to screening visit&#xD;
&#xD;
          5. Hospitalization within 60 days of the screening visit&#xD;
&#xD;
          6. Any condition that would place the subject at risk, interfere with participation in&#xD;
             the study&#xD;
&#xD;
          7. History of or positive human immunodeficiency virus (HIV) screen result at the&#xD;
             screening visit&#xD;
&#xD;
          8. History of certain other conditions&#xD;
&#xD;
          9. Positive urine, drug or alcohol screen result at screening&#xD;
&#xD;
         10. Known sensitivity to any of the components of the investigational product formulation&#xD;
&#xD;
         11. Participation in any clinical research study evaluating another investigational drug&#xD;
             or therapy within 30 days or at least 5 half-lives (whichever is longer), of the&#xD;
             investigational drug prior to the screening visit&#xD;
&#xD;
         12. Live/attenuated vaccinations within 12 weeks of screening or during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2012</study_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

